1. Home
  2. BLKB vs FOLD Comparison

BLKB vs FOLD Comparison

Compare BLKB & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLKB
  • FOLD
  • Stock Information
  • Founded
  • BLKB 1981
  • FOLD 2002
  • Country
  • BLKB United States
  • FOLD United States
  • Employees
  • BLKB N/A
  • FOLD N/A
  • Industry
  • BLKB Computer Software: Prepackaged Software
  • FOLD Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLKB Technology
  • FOLD Health Care
  • Exchange
  • BLKB Nasdaq
  • FOLD Nasdaq
  • Market Cap
  • BLKB 3.1B
  • FOLD 2.9B
  • IPO Year
  • BLKB 2004
  • FOLD 2007
  • Fundamental
  • Price
  • BLKB $61.50
  • FOLD $5.64
  • Analyst Decision
  • BLKB Hold
  • FOLD Buy
  • Analyst Count
  • BLKB 3
  • FOLD 10
  • Target Price
  • BLKB $78.67
  • FOLD $16.22
  • AVG Volume (30 Days)
  • BLKB 275.2K
  • FOLD 5.3M
  • Earning Date
  • BLKB 07-29-2025
  • FOLD 08-07-2025
  • Dividend Yield
  • BLKB N/A
  • FOLD N/A
  • EPS Growth
  • BLKB N/A
  • FOLD N/A
  • EPS
  • BLKB N/A
  • FOLD N/A
  • Revenue
  • BLKB $1,146,906,000.00
  • FOLD $543,141,000.00
  • Revenue This Year
  • BLKB N/A
  • FOLD $19.84
  • Revenue Next Year
  • BLKB $4.03
  • FOLD $23.18
  • P/E Ratio
  • BLKB N/A
  • FOLD N/A
  • Revenue Growth
  • BLKB 2.13
  • FOLD 28.25
  • 52 Week Low
  • BLKB $58.05
  • FOLD $5.62
  • 52 Week High
  • BLKB $88.95
  • FOLD $12.65
  • Technical
  • Relative Strength Index (RSI)
  • BLKB 47.03
  • FOLD 33.65
  • Support Level
  • BLKB $59.85
  • FOLD $6.00
  • Resistance Level
  • BLKB $62.50
  • FOLD $6.22
  • Average True Range (ATR)
  • BLKB 1.35
  • FOLD 0.19
  • MACD
  • BLKB -0.19
  • FOLD -0.01
  • Stochastic Oscillator
  • BLKB 36.34
  • FOLD 2.70

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: